ENPP2: A Potential Drug Target and Biomarker (G5168)

Target Name: ENPP2

NCBI ID: G5168

ENPP2

ENPP2: A Potential Drug Target and Biomarker

ENPP2, or Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (ISOFORM 4), is a protein that plays a crucial role in cellular signaling. It is a key enzyme in the ENPP family, which is involved in the regulation of DNA replication, transcription, and gene expression. ENPP2 has been identified as a potential drug target and biomarker due to its unique structure, function, and involvement in various diseases.

ENPP2 is a 25kDa protein that is expressed in various tissues, including brain, heart, skeletal muscles, and organs. It is a single-chain protein that contains a nucleotide-binding domain, a catalytic domain, and a carboxylic acid- rich domain. The nucleotide-binding domain is responsible for binding to DNA template, while the catalytic domain catalyzes the phosphorylation and dephosphorylation of the nucleotides, and the carboxylic acid-rich domain is involved in the regulation of the activity of the enzyme(3).

ENPP2 is involved in various cellular processes, including DNA replication, transcription, and gene expression. During DNA replication, ENPP2 is involved in the initiation of DNA synthesis, as it provides the necessary phosphate groups for the initiation of the replication process. ENPP2 is also involved in the regulation of gene expression by controlling the levels of phosphate groups, which play a critical role in the regulation of protein synthesis.

In addition to its role in cellular signaling, ENPP2 is also a potential biomarker for various diseases. For example, ENPP2 has been associated with various neurological diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The accumulation of ENPP2-containing protein in these diseases is thought to contribute to the development and progression of these conditions. Therefore, targeting ENPP2 with drugs or other therapeutic approaches may be a promising strategy for the treatment of these debilitating diseases.

ENPP2 has also been identified as a potential drug target for various other conditions, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, ENPP2 has been shown to be involved in the regulation of cell proliferation and has been linked to the development of various types of cancer. Additionally, ENPP2 has been shown to be involved in the regulation of neurotransmitter release and has been linked to the development and progression of neurodegenerative diseases.

In conclusion, ENPP2 is a protein that plays a critical role in cellular signaling and has been associated with various diseases. Its unique structure and function make it an attractive target for drug development. The potential drug targets and biomarkers for ENPP2 make it an promising strategy for the treatment of a variety of diseases.

Protein Name: Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Functions: Hydrolyzes lysophospholipids to produce the signaling molecule lysophosphatidic acid (LPA) in extracellular fluids (PubMed:15769751, PubMed:26371182, PubMed:27754931, PubMed:14500380, PubMed:12354767). Major substrate is lysophosphatidylcholine (PubMed:12176993, PubMed:27754931, PubMed:14500380). Can also act on sphingosylphosphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility (PubMed:14500380). Can hydrolyze, in vitro, bis-pNPP, to some extent pNP-TMP, and barely ATP (PubMed:15769751, PubMed:12176993). Involved in several motility-related processes such as angiogenesis and neurite outgrowth. Acts as an angiogenic factor by stimulating migration of smooth muscle cells and microtubule formation (PubMed:11559573). Stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein (PubMed:1733949). May have a role in induction of parturition (PubMed:12176993). Possible involvement in cell proliferation and adipose tissue development (Probable). Tumor cell motility-stimulating factor (PubMed:1733949, PubMed:11559573). Required for LPA production in activated platelets, cleaves the sn-1 lysophospholipids to generate sn-1 lysophosphatidic acids containing predominantly 18:2 and 20:4 fatty acids (PubMed:21393252). Shows a preference for the sn-1 to the sn-2 isomer of 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) (PubMed:21393252)

The "ENPP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENPP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets